Company profile: Allogene Therapeutics
1.1 - Company Overview
Company description
- Provider of allogeneic CAR T cell therapies via the AlloCAR T Product Platform, developing investigational treatments for blood cancers, solid tumors, and autoimmune diseases: cemacabtagene ansegedleucel (CD19) for large B-cell lymphoma and chronic lymphocytic leukemia; ALLO-316 (CD70) for clear cell renal cell carcinoma; ALLO-329 (CD19/CD70) for autoimmune diseases; ALLO-715 (BCMA) and ALLO-605 (BCMA TurboCAR) for multiple myeloma.
Products and services
- AlloCAR T™ Product Platform: Engineers an allogeneic CAR T framework leveraging healthy-donor T cells to create therapies for blood cancers, solid tumors, and autoimmune diseases
- Cemacabtagene Ansegedleucel (Cema-cel): Constructs an allogeneic CAR T therapy targeting CD19, studied in large B-cell lymphoma and chronic lymphocytic leukemia patient populations
- ALLO-605: Produces a TurboCAR-enabled BCMA-targeting CAR T therapy for multiple myeloma, incorporating TurboCAR technology within the treatment construct
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allogene Therapeutics
Human Genome Sciences
HQ: United States
Website
- Description: Provider of global healthcare focused on helping people do more, feel better, and live longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Human Genome Sciences company profile →
VBI Vaccines
HQ: United States
Website
- Description: Provider of novel biopharmaceutical technologies that seek to expand vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VBI Vaccines company profile →
Calico Labs
HQ: United States
Website
- Description: Provider of research and development focused on the biology that controls aging and lifespan; a Google-sponsored company researching the challenges of aging and disease to diminish their effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calico Labs company profile →
Autolus Therapeutics
HQ: United Kingdom
Website
- Description: Provider of next-generation programmed T cell therapies for cancer, leveraging T-cell programming and manufacturing technology. Pipeline includes CAR T products such as obe-cel (obecabtagene autoleucel) for adult ALL; AUTO1/22 for pediatric ALL; AUTO4 (TRBC1) and AUTO5 (TRBC2) for peripheral T-cell lymphoma; AUTO6NG (GD2) for neuroblastoma and other solid tumors; and AUTO8 (BCMA/CD19) for multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Autolus Therapeutics company profile →
Tetherex Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology therapeutics under development, including SelK2, a humanized monoclonal antibody targeting PSGL-1 for asthma and COPD, and SC-Ad6-1, a single-cycle adenovirus vector expressing the SARS-CoV-2 spike protein for intranasal or intramuscular administration to induce mucosal and systemic immunity against COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetherex Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allogene Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allogene Therapeutics
2.2 - Growth funds investing in similar companies to Allogene Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allogene Therapeutics
4.2 - Public trading comparable groups for Allogene Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →